66 trials (keyword fallback)
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Long Term Safety and Tolerability as Measured by the Incidence and Severity of Adverse Events and Clinical Laboratory Abnormalities — 73; 62; 36; 16 Participants
Myelofibrosis · Post-polycythemia Vera Myelofibrosis (PPV-MF) · Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Primary Myelofibrosis · Post-Polycythemia Vera · Myelofibrosis
Primary: Spleen Volume Response Rate (RR) — 35.8; 6.0 Percentage of Participants — p=<0.0001
Myelofibrosis (MF)
Primary: Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24 (SVR35W24) — 31.50; 63.20 percentage of participants — p=<0.0001
Myelofibrosis
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 5 Years — 2153; 830 Participants
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase · Primary Myelofibrosis · Secondary Myelofibrosis
Primary: Number of Participants With a Response — 15 Participants
Myelofibrosis · Polycythemia Vera · Thrombocytosis
Primary: Number of Participants With Adverse Events (AEs) — 30; 35; 47; 5 participants
MPN (Myeloproliferative Neoplasms)
Primary: Number of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 24 — 65; 1 participants — p=<0.0001
Primary Myelofibrosis (MF)
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 50; 46; 12; 5 Participants
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Part 1 and Part 2: Number of Subjects With Adverse Events and Serious Adverse Event — 0; 0; 0; 0 Participants
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Mean Percentage Change From Baseline in Spleen Volume at Week 24 — -14.9 Percentage change
Myelofibrosis
Primary: Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 48 — 28.5; 0 Percentage of Participants — p=<0.0001
Myelofibrosis
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants
Primary Myelofibrosis · Secondary Myelofibrosis
Primary: 2-year Overall Survival (OS) in Patients With Myelofibrosis (MF) Who Receive Treatment With a JAK Inhibitor Followed by an Allogeneic Transplant — 78.24 percentage of…
Primary Myelofibrosis · Post-polycythemia Vera Myelofibrosis · Post-essential Thrombocythemia Myelofibrosis
Primary: Total Symptom Score (TSS) Response Rate at Week 24 — 24.62; 9.23 Percentage of participants — p=0.0095